EPIOMIC EPIDEMIOLOGY SERIES: TAY–SACHS DISEASE FORECAST IN 19 MAJOR MARKETS 2018–2028

EPIOMIC EPIDEMIOLOGY SERIES: TAY–SACHS DISEASE FORECAST IN 19 MAJOR MARKETS 2018–2028

  • July 2018 •
  • 78 pages •
  • Report ID: 5472006 •
  • Format: PDF
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Tay Sachs Disease (TSD) in 19 Major Markets

Hexosaminidase A deficiency (HEX A deficiency) results in a group of neurodegenerative disorders caused by the dysfunctional activity of the specific glycosphingolipid GM2 ganglioside. The disease occurs when cell membrane components known as gangliosides, accumulate to toxic levels, particularly in neurons in the brain and spinal cord, leading to the destruction of neurons and interference with biological functions. The predominant HEX A deficiency is Tay-Sachs disease (TSD) with its common acute infantile variant, which begins around six months of age and usually results in death by the age of four. Alternative variants of the pathology are the juvenile and the adult-onset TSD types.

This report provides the current prevalent population for TSD disease across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Czech Republic, Portugal, Russia, Turkey, Saudi Arabia, Japan, China, India, Australia, Brazil) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, patients with main phenotypes and multiple symptoms of TSD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for TSD include:
•Visual problems

•Low muscle tone

•Seizures

•Neuromuscular abnormalities

•Speech disturbances

•Cerebellar dysfunctions/Impaired cognitive status

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
•Able to quantify patient populations in global TSD market to target the development of future products, pricing strategies and launch plans.

•Gain further insight into the prevalence of the subdivided types of TSD and identify patient segments with high potential.

•Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

•Provide a level of understanding on the impact from specific co-morbid conditions on TSD prevalent population.

•Identify sub-populations within TSD which require treatment.

•Gain an understanding of the specific markets that have the largest number of TSD patients.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.